


REMARKS

Applicants provisionally elect the species represented by formula XVIII :



(XVIII)

As required, Applicants identify claims 1, 2, 5, 6, 7, 9-13, 15, 21-29, 33, 69-72, 79-86, 88, and 89 as encompassing the alleged species disclosed in formula XVIII and illustrated on page 20 of the specification.

Claims 38, 58-62, and 67 have been cancelled. Claims 84-90 have been added. An equal number of independent claims have been cancelled as have been added. An equal number of dependent claims have been cancelled as have been added. As such no extra claim fee is believed to be required with the filing of this amendment. No argument is made with regard to patentable distinctiveness by this Response.

Applicants thank the Examiner for discussions January 9, 2005, February 10, and March 29, 2006. No agreements were reached.

New Claims

New claims 84-90 have been added to provide additional coverage for the invention, and so are not being presented for reasons related to patentability as defined in *Festo*. Claims 84-90 are directed at compounds and do not recite enzyme terminology in the claims.

CONCLUSION

Applicants believe that currently pending Claims 1-33, 68-74, and 79-90 are patentable. Applicants respectfully request that the Examiner grant early allowance of this application. The Examiner is invited to contact the undersigned agent for the applicants via telephone if such communication would expedite this application.

Respectfully submitted,



Lisa M. Seaney, Ph.D.
Registration No. 56,246
Agent for Applicants

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4200